分支链氨基酸转氨酶作为瘤治疗中的有希望的标

相关实验视频

Updated: Jul 12, 2026

06:32

Evaluation of Amino Acid Consumption in Cultured Bone Cells and Isolated Bone Shafts

Published on: April 13, 2022

Weiran Zhang¹, Jie Shen¹, Xuanyin Ding¹

¹Department of Thoracic Oncology, Cancer Institute of Jiangsu University, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.

Frontiers in cell and developmental biology

|February 20, 2026

概括

分支链氨基酸转氨酶 (BCATs) 通过改变新陈代谢和信号传递来驱动癌症生长和耐药性. 向BCAT提供了一个有希望的策略,以克服治疗耐药性和改善癌症治疗结果.

科学领域:

生物化学生物化学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

分支链氨基酸转氨酶 (BCAT),特别是BCAT1和BCAT2,是分支链氨基酸 (BCAA) 代谢中的关键酶.
异常的BCAT表达与许多癌症的发展和进展有关,包括胃癌,胰腺癌,肺癌和乳腺癌.

研究的目的:

审查BCAT在癌症进展中的多方面的作用,包括它们对瘤性途径和代谢重编程的影响.
探索BCATs对各种癌症类型治疗耐药性的贡献.
总结针对BCAT用于癌症治疗的当前和潜在的治疗策略.

主要方法:

文献综述综合了目前关于癌症中BCATs的研究.
对BCAT参与关键信号通路 (mTOR,PI3K/AKT,Wnt/β-catenin) 的分析.
检查BCATs在代谢重编程,表观遗传学和免疫逃避中的作用.

主要成果:

BCATs调节BCAA的新陈代谢,影响瘤信号通路,促进瘤的扩散,入侵和转移.
在各种恶性瘤中,BCAT与抗化学疗法,向疗法和内分泌疗法相关.
在瘤微环境中,BCATs有助于代谢适应,表观遗传改变和免疫逃避.

结论:

BCATs是瘤发生和治疗耐药性的重要驱动因素,代表潜在的生物标志物和治疗点.
通过酶抑制剂,饮食干预或组合疗法向BCAT,有望克服耐药性.
对BCAT机制的进一步研究可以为癌症治疗中的新型临床应用铺平道路.

关键词:

生物标志物生物标志物有分支链的氨基酸转氨基酶.药物耐药性耐药性药物耐药性瘤性途径的发生.瘤代谢瘤代谢

相关概念视频

03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

02:57

Targeted Cancer Therapies

01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...